DATE: May 13, 2021 (Updated)

TO: IHS & 638 Tribal Facilities & Pharmacies
     Fee-For-Service Providers
     Optum Network Pharmacies

FROM: Suzi Berman, RPh, AHCCCS Director of Pharmacy
      AHCCCS Division of Fee-For-Service Management (DFSM)

SUBJECT: Billing Information for COVID-19 Vaccine Administration Fees for Members 12 Years of Age and Older for the Pfizer Vaccine and 18 Years of Age and Older for the Moderna Vaccine and the Janssen Vaccine.

Provider Qualifications
The AHCCCS Fee-For-Service Program (FFS) shall reimburse COVID-19 vaccine administration fee(s) to the following AHCCCS registered providers:

- Pharmacies obtaining the vaccine directly from the federal government,
- IHS & 638 Tribal facilities administering the vaccine, and
- The Arizona Department of Health Services (ADHS) COVID-19 Onboarded providers.

Reimbursement is provided to AHCCCS registered pharmacies when the vaccine is administered by a pharmacist, or interns and technicians under the supervision of a pharmacist, who are certified by the Arizona State Board of Pharmacy consistent with the limitations of state law A.R.S §32-1974.

IHS & 638 Tribal Pharmacies
IHS and 638 Pharmacies may bill the current outpatient All Inclusive Rate (AIR) in effect on the date of service for the COVID-19 Vaccine administration fee(s) when administered by a pharmacist or interns and technicians under the supervision of a licensed pharmacist. The licensed pharmacist must have completed immunization training which also includes the use and administration of emergency medications. AHCCCS is also temporarily allowing IHS/638 pharmacies to be reimbursed an additional pharmacy AIR for COVID-19 administration fee(s) in addition to the limitation of one pharmacy AIR per day per member per facility. We will also continue to reimburse a second AIR for the flu vaccine. The limitation of 5 AIRs per day per member per facility will remain the same.

The IHS and 638 Pharmacies shall submit COVID-19 vaccine administration claims to the AHCCCS FFS Pharmacy Benefit Manager (PBM) point-of-sale system through OptumRx using the current process that is used today when billing prescription claims for the AIR.

Retroactive billing will be allowed for the administration of the COVID-19 vaccinations as noted below:

- 12/14/2020 for the Pfizer vaccine
- 12/18/2020 for the Moderna vaccine
- 2/27/2021 for the Janssen vaccine
**IHS & 638 Medical Claim Billing**

IHS and 638 Facilities administering the COVID-19 vaccine as a clinic service may bill the current outpatient AIR in effect on the date of service for the administration of the vaccine on a UB-04 for Title XIX AHCCCS members. The claim must include the NPI(s) of the ordering and rendering provider and the providers must be AHCCCS registered. For FFS KidsCare members, the facilities are to bill AHCCCS for the administration fee(s) noted in the table below using the CMS 1500 Form or in the 837P format. The facility may bill the AIR for the initial and second administration of the injection.

Retroactive billing will be allowed for the administration of the COVID-19 vaccinations as noted below:

- 12/14/2020 for the Pfizer vaccine
- 12/18/2020 for the Moderna vaccine
- 2/27/2021 for the Janssen vaccine

**OptumRx Retail Network Pharmacies (Non-IHS/638 Pharmacies)**

OptumRx shall reimburse the COVID-19 vaccine administration fees for AHCCCS members through the point-of-sale system when the pharmacy is AHCCCS registered, whether the pharmacy is in or out of OptumRx’s Pharmacy Network and the claim is submitted in accordance with the NCPDP guidance.

The pharmacy must follow the NCPDP billing guidance as noted below:

Billing for reimbursement of a free product (no associated cost) including an administration fee per NCPDP guidelines:

- The submitted Transaction Code (103-A3) is a “B1” (Claim Billing).
- The submitted Prescription/Service Reference Number Qualifier (455-EM) is a “1” (Rx Billing).
- The claim pricing segment follows the prescription claim request formula.
- The Product/Service ID (407-D7) should be submitted with the correct Product/Service ID Qualifier (436/E1) (in this example “03” (NDC))
- Product/Service ID (407-D7) contains the NDC Number of the vaccine or other product that was administered and obtained at zero cost.
- The Days’ Supply (405-D5) should be submitted with a value of “1”.
- The Quantity Dispensed (442-E7) should be submitted with the value that represents the quantity of drug product administered.
- The DUR/PPS Segment, with a “MA” (Medication Administered) in the Professional Service Code (440-E5), is submitted to identify the product was administered.
- The Incentive Amount Submitted (438-E3) is submitted to identify the pharmacy is seeking reimbursement for the administration of the product.
- The submission clarification code (420-DK)
  - Initial Dose(s) and Single Dose: Submission Clarification Code of 2 “Other Override” - defined as “Used when authorized by the payer in business cases not currently addressed by other SCC values to indicate the first dose of a multi-dose vaccine is being administered”
  - Final Dose: Submission Clarification Code of 6 “Starter Dose” - defined as “The pharmacist is indicating that the previous medication was a starter dose and now additional medication is needed to continue treatment to indicate the second dose of a multi-dose vaccine is being administered”
- The administration fee for COVID-19 vaccines is noted below:

  Dates of service 12/14/2020 through 3/14/2021
- Initial vaccine administration - $16.94
- Second vaccine administration - $28.39
- Single dose vaccine administration - $28.39

**Dates of service 3/15/2021 and after**
- Initial vaccine administration - $40.00
- Second vaccine administration - $40.00
- Single dose vaccine administration - $40.00
- Basis of Cost Determination (423-DN) should be submitted with the value “15” (Free product or no associated cost).

The table below provides the COVID-19 CPT codes and NDC codes to be used when submitting medical or POS claims for the vaccine administration fee(s).

**Pharmacies must submit the National Provider Identifier (NPI) of the pharmacy as the ordering and the rendering provider on the POS claim or if submitting a medical claim. The pharmacy provider must be AHCCCS registered.**

**FFS Provider Medical Claim Billing Requirements (Non-IHS/638 Providers)**

- COVID-19 vaccines are provided at no charge from the Federal government at this time.

- **Non-IHS/638 Tribal Providers** must submit medical claims for the COVID-19 vaccine administration fee(s) on a CMS-1500 claim form or in the 837P format. When billing for the vaccine itself, a cost for the vaccine greater than zero shall not be entered, on the CMS 1500 claim form, in the 837P format.

- **Non-IHS/638 Providers** must use the NPI(s) of the ordering and rendering provider on the CMS-1500 claim form or in the 837P format when billing for the vaccine administration fee(s). The ordering and rendering provider(s) must be registered with AHCCCS.

- Pharmacies must submit the National Provider Identifier (NPI) of the pharmacy as the ordering and rendering provider on the POS claim or if submitting a medical claim. The pharmacy provider must be AHCCCS registered.

- CPT codes to be used for claims submission for COVID-19 Vaccines and Administration are specific to the vaccine being administered and are provided in the table below. The NDC is not required on the CMS-1500 claim form or the 837P format.

- Retroactive billing will be allowed for the administration of the COVID-19 vaccinations noted below:
  - 12/14/2020 for the Pfizer vaccine
  - 12/18/2020, for the Moderna vaccine
  - 2/27/2021 for the Janssen vaccine

**Note:** When submitting medical claims, Providers may bill both administration fees on a single claim form when both vaccines have been administered or separate claims may be submitted once each vaccine administration is completed.
<table>
<thead>
<tr>
<th>Vaccine CPT Codes for Medical Claims</th>
<th>Vaccine / Procedure Name</th>
<th>Vaccine Descriptor</th>
<th>Vaccine NDC Codes for Pharmacy POS Claims</th>
<th>Minimum Dosing Interval (general guidelines)</th>
<th>AHCCCS Allowable Fees</th>
</tr>
</thead>
<tbody>
<tr>
<td>91300</td>
<td>Pfizer-Biontech Covid-19 Vaccine</td>
<td>Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use.</td>
<td>59267-1000-01 vial 59267-1000-02 carton 59267-1000-03 diluent</td>
<td>$0.00 - $0.01</td>
<td></td>
</tr>
<tr>
<td>0001A</td>
<td>Pfizer-Biontech Covid-19 Vaccine</td>
<td>ADM (Administration) SARCOCV2 30MCG/0.3ML1ST</td>
<td>59267-1000-01 vial 59267-1000-02 carton 59267-1000-03 diluent</td>
<td>$16.94 for dates of service prior to 3/15/2021 and $40.00 for dates of service 3/15/2021 and after</td>
<td>$16.94 for dates of service prior to 3/15/2021 and $40.00 for dates of service 3/15/2021 and after</td>
</tr>
<tr>
<td>0002A</td>
<td>Pfizer-Biontech Covid-19 Vaccine</td>
<td>ADM (Administration) SARCOCV2 30MCG/0.3ML2ND</td>
<td>59267-1000-01 vial 59267-1000-02 carton 59267-1000-03 diluent</td>
<td>$28.39 for dates of service prior to 3/15/2021 and $40.00 for dates of service 3/15/2021 and after</td>
<td></td>
</tr>
<tr>
<td>91301</td>
<td>Moderna Covid-19 Vaccine</td>
<td>Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use</td>
<td>80777-0273-10 vial 80777-0273-99 carton</td>
<td>$0.00 - $0.01</td>
<td></td>
</tr>
<tr>
<td>0011A</td>
<td>Moderna Covid-19 Vaccine Administration First Dose</td>
<td>ADM (Administration) SARCOCV2 100MCG/0.5ML1ST</td>
<td>80777-0273-10 vial 80777-0273-99 carton</td>
<td>$16.94 for dates of service prior to 3/15/2021 and $40.00 for dates of service 3/15/2021 and after</td>
<td>$16.94 for dates of service prior to 3/15/2021 and $40.00 for dates of service 3/15/2021 and after</td>
</tr>
<tr>
<td>0012A</td>
<td>Moderna Covid-19 Vaccine Administration Second Dose</td>
<td>ADM (Administration) SARCOCV2 100MCG/0.5ML2ND</td>
<td>80777-0273-10 vial 80777-0273-99 carton</td>
<td>$28.39 for dates of service prior to 3/15/2021 and $40.00 for dates of service 3/15/2021 and after</td>
<td></td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Details</td>
<td>CPT Code</td>
<td>Code</td>
<td>Billing Information</td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------------</td>
<td>------</td>
<td>-------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>91303</td>
<td>Janssen COVID-19 Vaccine</td>
<td>Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10¹⁰ viral particles/0.5mL dosage, for intramuscular use</td>
<td></td>
<td></td>
<td>3/15/2021 and after</td>
</tr>
<tr>
<td>0031A</td>
<td>Janssen COVID-19 Vaccine Administration Single Dose</td>
<td>ADM SARSCOV2 5x10¹⁰ viral particles/0.5mL dosage</td>
<td>59676-0580-05</td>
<td></td>
<td>59676-0580-15 carton</td>
</tr>
</tbody>
</table>

**Billing Example - Paper Professional CMS-1500 Claim Form:**

<table>
<thead>
<tr>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>E</th>
<th>F</th>
<th>G</th>
<th>H</th>
<th>I</th>
<th>J</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dates of Service</td>
<td>Place of Service</td>
<td>EMG</td>
<td>Procedure, Services or Supplies</td>
<td>Diagnosis Pointer</td>
<td>$ Charges</td>
<td>Days or Units</td>
<td>EPSDT/Family Planning</td>
<td>ID Qual</td>
<td>Rendering Provider</td>
</tr>
<tr>
<td>12/15/2020 - 12/15/2020</td>
<td>31</td>
<td>N</td>
<td>0001A</td>
<td>A</td>
<td>16.94</td>
<td>1</td>
<td>XX</td>
<td>123456789</td>
<td></td>
</tr>
<tr>
<td>1/4/2021 - 1/4/2021</td>
<td>31</td>
<td>N</td>
<td>0002A</td>
<td>A</td>
<td>28.39</td>
<td>1</td>
<td>XX</td>
<td>123456789</td>
<td></td>
</tr>
</tbody>
</table>

**Emergency Use Authorization Timeline**

The following COVID-19 vaccinations were approved for Emergency Use Authorization, for age groups as delineated below:

- **Pfizer**
  - Approved for ages 16+ with dates of service 12/14/2020 to 5/12/2021.
  - Approved for ages 12+ with dates of service 5/13/2021 and after.

- **Moderna**
  - Approved for ages 18+ with dates of service 12/18/2020 and after.

- **Janssen**
  - Approved for ages 18+ with dates of service 2/27/2021 and after.